Seer EBITDA Margin 2020-2022 | SEER
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Seer (SEER) over the last 10 years. The current EBITDA margin for Seer as of March 31, 2022 is .
| Seer EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2022-03-31 |
$0.01B |
$-0.08B |
-833.33% |
| 2021-12-31 |
$0.01B |
$-0.07B |
-1133.33% |
| 2021-09-30 |
$0.00B |
$-0.06B |
-2033.33% |
| 2021-06-30 |
$0.00B |
$-0.05B |
-5200.00% |
| 2021-03-31 |
$0.00B |
$-0.04B |
inf% |
| 2020-12-31 |
$0.00B |
$-0.03B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.613B |
$0.007B |
|
Seer Inc. is a life sciences company. It engages in developing Proteograph(TM), which is an integrated solution consisting of consumables, automation instrumentation and proprietary software. Seer Inc. is based in REDWOOD CITY, Calif.
|
